Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Tuesday, Wall Street Zen reports.
A number of other research analysts also recently issued reports on AKBA. BTIG Research reaffirmed a “buy” rating and issued a $4.00 price objective on shares of Akebia Therapeutics in a research report on Tuesday, September 15th. Piper Sandler decreased their target price on shares of Akebia Therapeutics to $2.00 and set an “overweight” rating for the company in a research report on Monday. Westpark Capital began coverage on shares of Akebia Therapeutics in a research report on Tuesday, September 8th. They set a “buy” rating and a $4.50 target price for the company. HC Wainwright restated a “buy” rating on shares of Akebia Therapeutics in a research note on Thursday, August 6th. Finally, Weiss Ratings lowered shares of Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $3.50.
Get Our Latest Stock Analysis on Akebia Therapeutics
Akebia Therapeutics Trading Up 2.1%
AKBA opened at $0.41 on Tuesday. The business’s 50-day moving average is $0.74 and its two-hundred day moving average is $1.09. Akebia Therapeutics has a 1 year low of $0.36 and a 1 year high of $1.73. The company has a current ratio of 1.36, a quick ratio of 1.24 and a debt-to-equity ratio of 0.63.
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the consensus estimate of ($0.04). The business had revenue of $36.90 million during the quarter, compared to analyst estimates of $46.94 million. Akebia Therapeutics had a negative net margin of 22.60% and a negative return on equity of 156.59%. Sell-side analysts anticipate that Akebia Therapeutics will post -0.19 EPS for the current fiscal year.
Institutional Investors Weigh In On Akebia Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AKBA. Nantahala Capital Management LLC purchased a new position in shares of Akebia Therapeutics in the 2nd quarter valued at approximately $2,280,000. BlackRock Inc. acquired a new stake in Akebia Therapeutics in the 2nd quarter worth approximately $22,784,000. Bank of New York Mellon Corp purchased a new stake in Akebia Therapeutics during the 2nd quarter worth approximately $706,000. Hsbc Holdings PLC purchased a new stake in Akebia Therapeutics during the 2nd quarter worth approximately $27,000. Finally, Canada Pension Plan Investment Board purchased a new stake in Akebia Therapeutics during the 2nd quarter worth approximately $369,000. 33.92% of the stock is currently owned by hedge funds and other institutional investors.
About Akebia Therapeutics
Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for people affected by kidney disease. Founded in 2007 and based in Cambridge, Massachusetts, the company’s work has centered on anemia and other complications associated with chronic kidney disease. Its products include Vafseo (vadadustat), an oral treatment for anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months, and Auryxia (ferric citrate).
Further Reading
- Five stocks we like better than Akebia Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
